Kliniske undersøgelser viste ingen behandlingsrelaterede, alvorlige bivirkninger, og toleransen synes upåvirket af køn, alder og sygdomsgrad.
The clinical studies showed no treatment-related serious AEs and tolerability seems to be unaffected by gender, age or disease severity.